上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Dihydroberberine 纯度: 98.44%
Dihydroberberine 可抑制人类以太相关基因 (hERG) 通道,显着降低热休克蛋白 90 (Hsp90) 的表达及其与 hERG 的相互作用。Dihydroberberine 具有抗炎,抗动脉粥样硬化,降血脂和抗肿瘤活性。
Dihydroberberine Chemical Structure
CAS No. : 483-15-8
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
5 mg | ¥1100 | In-stock | |
10 mg | ¥1850 | In-stock | |
25 mg | ¥3400 | In-stock | |
50 mg | 询价 | ||
100 mg | 询价 |
* Please select Quantity before adding items.
Dihydroberberine 相关产品
•相关化合物库:
- Natural Product Library Plus
- Bioactive Compound Library Plus
- Cell Cycle/DNA Damage Compound Library
- Immunology/Inflammation Compound Library
- Membrane Transporter/Ion Channel Compound Library
- Metabolism/Protease Compound Library
- Natural Product Library
- Anti-Cancer Compound Library
- Anti-Aging Compound Library
- Anti-Cardiovascular Disease Compound Library
- Endoplasmic Reticulum Stress Compound Library
- Pyroptosis Compound Library
- Cytoskeleton Compound Library
- Anti-Alzheimer’s Disease Compound Library
- Neurodegenerative Disease-related Compound Library
生物活性 |
Dihydroberberine inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces heat shock protein 90 (Hsp90) expression and its interaction with hERG. Dihydroberberine has anti-inflammatory, anti-atherosclerotic, hypolipidemic and antitumor activities[1]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
337.37 |
||||||||||||||||
Formula |
C20H19NO4 |
||||||||||||||||
CAS 号 |
483-15-8 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 16.67 mg/mL (49.41 mM; ultrasonic and warming and heat to 60°C) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务